ArticleJournal of molecular neuroscience : MN2018
MiR-29a-Mediated CD133 Expression Contributes to Cisplatin Resistance in CD133
Article in Journal of molecular neuroscience : MN, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 32 citations in OpenAlex.
- Unmasking the Deceptive Nature of Cancer Stem Cells: The Role of CD133 in Revealing Their Secrets.International journal of molecular sciences · 2023Review
- Non-coding RNAs and glioma: Focus on cancer stem cells.Molecular therapy oncolytics · 2022Review
- MicroRNA-433-3p enhances chemosensitivity of glioma to cisplatin by downregulating NR5A2.Brain and behavior · 2022Article
- Review
- NcRNAs: Multi‑angle participation in the regulation of glioma chemotherapy resistance (Review).International journal of oncology · 2022Review
- MicroRNA-485-5p inhibits glioblastoma progression by suppressing E2F transcription factor 1 under cisplatin treatment.Bioengineered · 2021Article
- miR-29a-3p enhances the radiosensitivity of oral squamous cell carcinoma cells by inhibiting ADAM12.European journal of histochemistry : EJH · 2021Article
- MicroRNAs at the Crossroad of the Dichotomic Pathway Cell Death vs. Stemness in Neural Somatic and Cancer Stem Cells: Implications and Therapeutic Strategies.International journal of molecular sciences · 2020Review
- Molecular and Cellular Complexity of Glioma. Focus on Tumour Microenvironment and the Use of Molecular and Imaging Biomarkers to Overcome Treatment Resistance.International journal of molecular sciences · 2020Review
- The Significance of MicroRNAs Expression in Regulation of Extracellular Matrix and Other Drug Resistant Genes in Drug Resistant Ovarian Cancer Cell Lines.International journal of molecular sciences · 2020Article
- Role of non-coding RNAs and RNA modifiers in cancer therapy resistance.Molecular cancer · 2020Review
- Molecular Heterogeneity and Immunosuppressive Microenvironment in Glioblastoma.Frontiers in immunology · 2020Review
- ACT001, a novel PAI-1 inhibitor, exerts synergistic effects in combination with cisplatin by inhibiting PI3K/AKT pathway in glioma.Cell death & disease · 2019Article
- MicroRNA-29a inhibits glioblastoma stem cells and tumor growth by regulating the PDGF pathway.Journal of neuro-oncology · 2019Article
- Current and Future Trends on Diagnosis and Prognosis of Glioblastoma: From Molecular Biology to Proteomics.Cells · 2019Review
- miR-152-3p Sensitizes Glioblastoma Cells Towards Cisplatin Via Regulation Of SOS1.OncoTargets and therapy · 2019Article
- The Development and Applications of a Dual Optical Imaging System for Studying Glioma Stem Cells.Molecular imagingArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
CD133 positive (CD133
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.